argenx SE (EBR: ARGX)

Market Cap	37.81B
Revenue (ttm)	1.71B
Net Income (ttm)	-36.13M
Shares Out	60.37M
EPS (ttm)	-0.61
PE Ratio	n/a
Forward PE	82.98
Dividend	n/a
Ex-Dividend Date	n/a

Volume	40,272
Average Volume	63,252
Open	637.00
Previous Close	634.40
Day's Range	624.60 - 640.00
52-Week Range	322.50 - 658.00
Beta	0.25
RSI	60.74
Earnings Date	Feb 27, 2025

About argenx SE

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 1,148
• Stock Exchange: Euronext Brussels
• Ticker Symbol: ARGX

Financial Performance

In 2023, argenx SE's revenue was $1.27 billion, an increase of 187.66% compared to the previous year's $441.01 million. Losses were -$295.05 million, -58.42% less than in 2022.

Financial numbers in USD